Vipadenant
Parkinson's disease; also reverses adenosine-pathway tumor immune evasion
- CAS No.
- 442908-10-3
- Indication Class
- CNS / Psychiatry
- Patent Expiry
- Off-patent · 2020 (to verify)
- Therapeutic Area
- 肿瘤免疫 / 神经
- Target / Mechanism
- ADORA2A
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- 2000s compound patent; expired per 20-yr term estimate — to be verified
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An A2A adenosine-receptor antagonist spanning both neurodegeneration and tumor immunotherapy, a dual-scenario molecule with rising research interest.
肿瘤免疫 / 神经 · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Vipadenant is an experimental small molecule drug primarily developed and studied as an antagonist of the adenosine A₂A receptor. It has been developed for central nervous system diseases, especially Parkinson's disease, and its potential in the field of tumor immunity is currently being explored.
Supply source: Unibest · Vipadenant, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.